GSK and Fleming Initiative announce AMR research programs

Nov. 18, 2025

GSK plc and the Fleming Initiative have announced six major new research programs to find new ways to slow the progress of antimicrobial resistance (AMR). The Fleming Initiative is a collaboration established by Imperial College London and Imperial College Healthcare NHS Trust to help tackle AMR. Each of the new programs will begin by early next year and are fully funded for 3 years.

BioWorld Science Artificial intelligence Drug design, drug delivery and technologies Infection

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...